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Transforming growth-factor b (TGFb) has been impli-
cated in T helper 17 (Th17) cell biology and in
triggering expression of interleukin-17A (IL-17A),
which is a key Th17 cell cytokine. Deregulated
TGFb receptor (TGFbR) signaling has been impli-
cated in Th17-cell-mediated autoimmune pathogen-
esis. Nevertheless, the full molecular mechanisms
involved in the activation of the TGFbR pathway in
driving IL-17A expression remain unknown. Here,
we identified protein kinase C a (PKCa) as a signaling
intermediate specific to the Th17 cell subset in
the activation of TGFbRI. We have shown that
PKCa physically interacts and functionally cooper-
ates with TGFbRI to promote robust SMAD2-3
activation. Furthermore, PKCa-deficient (Prkca/)
cells demonstrated a defect in SMAD-dependent
IL-2 suppression, as well as decreased STAT3 DNA
binding within the Il17a promoter. Consistently,
Prkca/ cells failed to mount appropriate IL-17A,
but not IL-17F, responses in vitro and were resistant
to induction of Th17-cell-dependent experimental
autoimmune encephalomyelitis in vivo.
INTRODUCTION
The discovery of interleukin-17 (IL-17)-producing T helper 17
(Th17) cells has markedly changed our view of Th cell dif-
ferentiation and T-cell-mediated pathogenesis of autoimmune
diseases. A major research effort has been focused on the iden-
tification of signaling mediators that regulate Th17 cell differenti-
ation, yet how Th17 cell function is initiated and maintained is
an area of active research. Deregulated transforming growth-
factor b (TGFb) receptor (TGFbR) signaling has been implicated
in Th17 cell autoimmune pathogenesis (Bettelli et al., 2006; Man-
gan et al., 2006; Veldhoen et al., 2006a). Among other factors,
TGFb critically promotes Th17-cell-mediated IL-17A responses
(Lee et al., 2009; Volpe et al., 2008; Wilson et al., 2010). A crucial
role of TGFb in experimental autoimmune encephalomyelitis
(EAE) was highlighted by the finding that mice expressing domi-nant-negative TGFbRII confer resistance to EAE induction
through a reduction in pathogenic Th17 cells (Veldhoen et al.,
2006b). Accordingly, elevated IL-17A levels have been detected
in brain lesions and cerebrospinal fluid of individuals suffering
from multiple sclerosis (MS), a Th17-cell-dependent inflamma-
tory CNS-demyelinating disease (Lock et al., 2002; Matusevicius
et al., 1999), and of mice affected by EAE (Cua et al., 2003;
Langrish et al., 2005). TGFb initiates its cellular function by
binding to TGFbRII, which then activates TGFbRI activity
through phosphorylation of several residues in the core of the
GS domain. TGFbRI then propagates the signal by inducing
SMAD2-3 phosphorylation, which subsequently leads to nuclear
influx, SMAD2-3 DNA binding, and the transcriptional activation
of several target genes (Shi and Massague´, 2003). However,
the complete molecular mechanisms involved in TGFbR sig-
naling, as well as potential Th-cell-selective mechanisms, remain
elusive. The protein kinase C (PKC) family comprises nine mam-
malian isotypes of serine-threonine protein kinases that play
distinct roles in signal-transduction pathways. Besides the
PKCq isotype (Isakov and Altman, 2002), key functions for the
Ca2+-phospholipid-dependent PKCa isotype during T cell
activation have been reported (Gruber et al., 2009; Pfeifhofer
et al., 2006). Further evidence for the relevance of PKCa has
been provided by the identification of polymorphisms associated
with greater risk of MS (Barton et al., 2004; Saarela et al., 2006).
Despite this potential importance of PKCa in Th17-cell-mediated
autoimmunity, the molecular aspects of PKCa function in Th17
cells and its physiological effector substrates have remained bio-
chemically undefined. In the present study, we reveal a critical
positive regulatory role of PKCa as a Th17-cell-selective inter-
mediate of TGFbRI in directly regulating the kinase activity of
TGFbRI, which itself activates SMAD2-3, maintains effective
IL-17A responses, and thereby drives the pathogenesis of
Th17-cell-mediated autoimmune diseases. This PKCa-TGFbRI
kinase cooperation extends the paradigm of TGFbRI regulation
in Th17 cell biology.
RESULTS
PKCa Positively Regulates IL-17A-Specific Th17 Cell
Effector Function
The examination of PKCamRNA expression in different CD4+ Th
cell subsets revealed that PKCa is substantially upregulated in
in-vitro-differentiated Th17 cell cultures (Figure 1A). However,Immunity 38, 41–52, January 24, 2013 ª2013 Elsevier Inc. 41
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Figure 1. PKCa Is a Positive Regulator of Th17 Cell Effector Functions In Vitro and In Vivo
Naive CD4+ T cells were cultured under indicated Th-cell-polarizing conditions for 3 days. Error bars represent ± SEM. Data in (A)–(G) were derived from at least
three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001. (See also Figure S1).
(legend continued on next page)
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Table 1. Clinical Parameters of MOG35-55-Induced EAE
Genotype
Incidence
(ScoreR 0.5)
Onset Day
(Mean ± SEM)
Maximum Score
(Mean ± SEM)
WT 100.00% (22/22) 10.89 ± 0.98 2.03 ± 0.22
Prkca/ 78.95% (15/19) 12.00 ± 1.39 0.80 ± 0.17***
The results are shown as the mean ± SEM and indicate the total number
of individual mice in three independent experiments. The following abbre-
viation is used: WT, wild-type. ***p < 0.001.
Immunity
PKCa Is a Positive Regulator of TGFbR Functionexpression analysis of classical PKCb, novel PKCq, and PKCε,
or atypical PKCi and PKCz family members, revealed no Th17-
cell-specific upregulation (Figure S1A, available online). Expres-
sion-pattern analysis of key cytokines or transcription factors of
wild-type (WT) Th cell types confirmed specific and efficient
differentiation into the distinct effector Th cell lineages (Fig-
ure S1B). The loss of PKCa preserved the effector responses
of Th1-cell-mediated interferon-g (IFN-g), Th2-cell-mediated
IL-4, and inducible regulatory T (iTreg)-cell-mediated IL-10 (Fig-
ure 1B). Strikingly, the secretion of IL-17A was notably reduced
in PKCa-deficient (Prkca/) Th17 cells (Figure 1C). Of note,
expression of the two main Th17-cell-linage-specific transcrip-
tion factors, ROR-gt and ROR-a (Ivanov et al., 2006; Yang
et al., 2008b) (Figure 1D), as well as the transcription factors
RUNX1, AHR, and IRF4 (Figure S1C), which are related to Th17
cell development, was comparable between Prkca/ and WT
Th17 cells. The levels of IL-23R and IL-12Rb2 mRNA (Fig-
ure S1D), the surface receptor expression of CCR6 (Figure S1E),
and the secretion responses of IL-21, IL-22, granulocyte-macro-
phage colony-stimulating factor (GM-CSF), TGFb, and tumor
necrosis factor a (TNF-a) (Figure 1E), which are all connected
to Th17 cell effector functions (Gutcher et al., 2011; Korn et al.,
2009), were not altered between PKCa-proficient and PKCa-de-
ficient Th17 cells. A critical mechanism of effector Th17 cell
establishment represents the IL-6-triggered activation of
STAT3 (Yang et al., 2007). However, immunoblot experiments
showed no differences in (p)STAT3 levels between Prkca/
and WT CD4+ T cells, stimulated with either IL-6 or TGFb alone
or in combination, suggesting that PKCa does not play a role
in themodulation of membrane-proximal signaling events down-
stream of the IL-6 receptor. In addition, the mRNA of IL-6Rawas
equally expressed between both genotypes (Figures S1F–S1G
and data not shown). IL-17A and IL-17F, which are encoded
within the same locus, are the most homologous IL-17 family
members in that they have 50% identity in amino acid sequence
(Hymowitz et al., 2001). However, in strict contrast to the barely
detectable IL-17A mRNA expression (Figure 1F), IL-17F mRNA
expression (Figure 1G) remained comparable between WT and
Prkca/ Th17 cells. To experimentally reconfirm this selective
regulation of IL-17A, but not IL-17F, we cocultured naive CD4+
OT-II T cells together with OVA323-339-primed dendritic cells
(DCs) under Th17 cell conditions. As a result, when compared
to WT OT-II Th17 cells, Prkca/ OT-II Th17 cells differentiated
into a strongly reduced population of IL-17A+IL-17F cells but
an equal population of IL-17AIL-17F+ cells (Figure 1H and Fig-
ure S1H). As a control, defective IL-17A production in Prkca/(A) PKCa mRNA is highly expressed in Th17 cells.
(B–D) Production of IFN-g (B, left), IL-4 (B, middle), IL-10 (B, right), and IL-17A (C) w
PKCa in CD4+ T cells. The mRNA expression of ROR-gt (D, left) and ROR-a (D,
(E) Amounts of IL-21, IL-22, GM-CSF, TGFb, and TNF-a were analyzed.
(F and G) The mRNA expression of IL-17A (F) and IL-17F (G) was analyzed by qR
(H) Prkca+/+ or Prkca/ naive CD4+ OT-II T cells were stimulated with OVA323-3
IL-17F (Va2TCR+ gated) were analyzed by flow cytometry. Data were derived fro
(I) Disease time course combining three independent experiments of EAE in WT
(J and K) Mononuclear cells were isolated from the brain, spinal cord, and drainin
IFN-g (CD4+ gated). Representative fluorescence-activated cell sorting (FACS) p
and Prkca/ mice are displayed (right panel). Data were derived from three mic
(L–N) Amounts of IL-17A (L, left), IFN-g (L, right), GM-CSF (M), and IL-2 (N) in the
obtained from five separate mice per group.Th17 cells did not correlate with an increased conversion to
Th1 or iTreg cells under Th17-cell-polarizing conditions in that
they displayed no increase in T-BET or FOXP3, the signature
transcription factors of Th1 and iTreg cells, respectively (Fig-
ure S2A). The results were attributable neither to survival defects
nor to a hindered proliferation of Prkca/ Th17 cells (Figures
S2B and S2C and data not shown). Taken together, these results
indicate that the absence of PKCa leads to a profound selective
inhibition of Th17 cell effector function at the transcriptional level
of IL-17A.
PKCa Deficiency Protects against EAE Induced by
Myelin Oligodendrocyte Glycoprotein35-55
These observations prompted us to analyze the potential role of
PKCa in Th17-cell-based inflammatory immune pathogenesis
in vivo. Thus, we determined the susceptibility of Prkca/
mice to EAE. We immunized WT and Prkca/ mice with myelin
oligodendrocyte glycoprotein35-55 (MOG33-55) and monitored
them for clinical signs of EAE. As expected, all WT mice devel-
oped EAE; in contrast, Prkca/ mice displayed a slightly de-
layed onset, indicating that priming events might be altered.
Moreover, the absence of PKCa almost completely inhibited
EAE disease development (Figure 1I and Table 1). At the peak
of clinical disease signs (day 14), infiltrating CD4+ cells from
the brain, spinal cord, and draining lymph nodes were analyzed
by flow cytometry. The absolute numbers of CD4+ mononuclear
cells (Figure S2D) and the percentage of CD4+ROR-gt+ cells (Fig-
ure 1J) remainedwithin a normal range between both genotypes.
AlthoughWT and Prkca/ Th17 cells generated in vitro produce
only marginal amounts of IFN-g (Figures S2E and S2F), Th17
cells generated in vivo often coproduce IFN-g during EAE (Ab-
romson-Leeman et al., 2009; Hirota et al., 2011; Ivanov et al.,
2006). However, IL-17A+ and IFN-g+ CD4+ CNS-infiltrating cells,
as well as IL-17A+IFN-g+ CD4+ CNS-infiltrating cells, were sig-
nificantly reduced in Prkca/ mice compared to WT mice (Fig-
ure 1K and right panels). Consistently, ex vivo recall-responseas determined. Immunoblotting (IB) (C, inset) indicates the efficient deletion of
right) was analyzed by quantitative RT-PCR (qRT-PCR).
T-PCR.
39-pulsed DCs under Th17-cell-polarizing conditions. Intracellular IL-17A and
m two independent experiments of three mice per group.
(n = 22) or Prkca/ (n = 19) mice.
g lymph nodes and were stained for intracellular ROR-gt (J) or IL-17A (K) and
lots (CD4+-gated) of IL-17A- and IFN-g-expressing CNS-infiltrating cells in WT
e per group per experiment from two independent experiments.
supernatant of EAE-mice splenocytes restimulated with MOG35-55. Data were
Immunity 38, 41–52, January 24, 2013 ª2013 Elsevier Inc. 43
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PKCa Is a Positive Regulator of TGFbR Functionanalysis at the priming phase of the disease (day 10 after
MOG35-55 immunization) revealed strongly decreased values of
both IL-17A and IFN-g (Figure 1L). GM-CSF is also known to
play a role during EAE (McQualter et al., 2001), yet its levels re-
mained unaffected in EAE-recall assays (Figure 1M). Strikingly,
severely increased levels of IL-2 in MOG35-55-antigen-restimu-
lated Prkca/ splenocytes were detected (Figure 1N). Collec-
tively, these data demonstrate that PKCa is essential for the
priming and effector phases of EAE.
It has been shown that CD4+CD25+FOXP3+ Treg cells
contribute to EAEdisease amelioration by suppressing autoreac-
tive effector Th cell expansion (O’Connor and Anderton, 2008).
By observing reduced FOXP3+ cell infiltrates in Prkca/ mice
(Figure S2G), we excluded the involvement of FOXP3+ Treg cells
in the EAE protection of Prkca/ mice during acute disease.
Consistently, and again in contrast to analysis of Th17 cells,
phenotypical analysis of Prkca/ iTreg cells revealed a dispens-
able role of PKCa in iTreg cell effector responses, as reflected
by FOXP3mRNAexpression (Figure S2H), the suppressive capa-
bilities in dampening Th cell effector responses, and the unal-
tered TGFbR-SMAD2-3 activation responses (data not shown).
Furthermore, we could demonstrate that under all investigated
doses of TGFb during iTreg cell differentiation, the fraction of
CD4+CD25+FOXP3+ cells was comparable between the geno-
types (Figure S2I). Of note, no developmental defect was
detected in the generation of CD4+CD25+FOXP3+ natural regula-
tory T (nTreg) cells in the absence of PKCa (Figure S2J). Collec-
tively, these results provide evidence that PKCa is not required to
effectively induce iTreg cell functions and reveal an unexpected,
subset-selective role for PKCa in Th17 cells.
To evaluate a potential CD4+ T-cell-intrinsic function of
PKCa in vivo, we transferred ex vivo MOG35-55-antigen-re-
stimulated, CD4+-enriched, Th17-differentiated cells from either
MOG35-55-immunized WT or Prkca
/ mice into syngeneic WT
recipient mice. Prior to the adoptive cell transfer, the extent
of MOG35-55-specific Th17 cell differentiation was validated. A
severely impaired antigen-specific immune response, featured
by diminished frequencies of IL-17A+IFN-g, IL-17AIFN-g+,
and IL-17A+IFN-g+ CD4+ T cells, was demonstrated in the
Prkca/ cells (Figures 2A and 2B). In addition, analysis of culture
supernatants demonstrated considerably reduced IL-17A and
IFN-g levels inPrkca/ cells (Figure 2C). However, the total pop-
ulation of CD4+ROR-gt+ cells prior to adoptive cell transfer was
comparable between genotypes (Figures 2D and 2E), excluding
an artifact due to lower CD4+ Th17 cell frequencies between
genotypes in the inoculum. The development of EAE disease
severity in mice that received Prkca/ CD4+ Th17 cells was
markedly reduced, and the onset of clinical EAE signs was sig-
nificantly delayed in these mice compared to those animals
receiving WT cells (Figure 2F and Table 2). These observations
indicate that MOG35-55-specific CD4
+ Th17 cells from Prkca/
mice are unable to efficiently induce EAE in recipient mice.
DCs are critical accessory cells during EAE and produce inflam-
matory cytokines, which are required for Th17 cell development
in vivo (Korn et al., 2009; Veldhoen et al., 2006a). In order to
exclude the possibility that impaired Th17 cell development in
Prkca/ mice is caused by a defect in DCs, we evaluated the
functionality of Prkca/ DCs. The critical DC markers CD86
and CD40 were appropriately expressed on the surface of44 Immunity 38, 41–52, January 24, 2013 ª2013 Elsevier Inc.Prkca/ DCs (Figure S3A). Additionally, lipopolysaccharide
(LPS)-stimulated Prkca/ DCs did not show impaired IL-6,
IFN-g, or TNF-a responses (Figure S3B). Moreover, a coculture
of naive WT or Prkca/ CD4+ OT-II T cells together with
OVA323-339-pulsed WT or Prkca
/ DCs indicated that Prkca/
DCs were capable of supporting Th17 cell development nor-
mally. However, the percentage of the CD4+IL-17A+ T cell
population of Prkca/ mice was strongly reduced regardless
of the origin of the cocultured DCs (Figure 2G). Although we
cannot exclude the existence of a Th17-cell-extrinsic role of
PKCa, these experiments validate PKCa as a critical player in
Th17-cell-driven neuroinflammatory autoimmune disease.
PKCa Is an Essential Regulator of the TGFbR-SMAD-
Signaling Pathway
To elucidate the mechanistic basis of the decreased IL-17A
expression found in Prkca/ Th17 cells, we cultured WT and
PKCa-deficient naive CD4+ T cells under distinct Th17 cell cyto-
kinemilieus. The stimulations thatwere performed in the absence
of TGFb did not reveal gross differences in IL-17A expression.
However, when TGFb was applied in combination with IL-6,
IL-23, or IL-1a, Prkca/ Th17 cells, compared to WT Th17 cells,
exhibited remarkably reduced IL-17A secretion responses (Fig-
ure 3A), indicating defective TGFbR signaling. This finding was
secondary to neither downregulated expression of TGFbRI and
TGFbRII mRNA nor reduced TGFbRI and TGFbRII protein
expression (Figures 3B–3D). Remarkably, the observed reduced
TGFbR-mediated IL-17A-secretion response in Prkca/ Th17
cells was especially prominent at high TGFb concentrations
(Figure 3E). However, IL-17F remained unaffected under these
conditions (Figure 3F). Strikingly, confocal-microscopy analysis
of endogenously stained PKCa and TGFbRI identified a constitu-
tive and TGFb-inducible colocalization of these two proteins
in primary human CD4+ peripheral-blood mononuclear cells
(PBMCs) (Figures 3G and 3H). This PKCa-TGFbRI-colocalization
complex peaked at 5 minutes and remained elevated for at least
1 hour of TGFb stimulation. As a control, neither PKCa nor
TGFbRI colocalized with the transmembrane IL-6R subunit
gp130 (Figures 3I and 3J). Furthermore, a constitutive and
TGFb-inducible physical interaction between the endogenous
PKCa and TGFbRI proteins in primary T cells was confirmed by
coimmunoprecipitation (Figure 3K). Interestingly, PKCa mRNA
expression in CD4+ T cells was inducible by TGFb (Figure 3L).
However, mRNA expression of PKCq under similar conditions re-
mained unaffected (data not shown). Several groups showed that
TGFb directly upregulates PKCa protein (Chen et al., 2010; Zhou
et al., 2010) and mRNA levels (Gao et al., 2003; Ranganathan
et al., 2007). To investigate the PKCa domains that are capable
of physically interacting with TGFbRI, we cotransfected the
HIS6-tagged WT PKCa, the constitutively active PKCa mutant,
or the catalytic subdomain of PKCa with a FLAG-tagged WT
TGFbRI expression vector in human embryonic kidney (HEK)
293T cells. Here, pulldown assays showed that the catalytic frag-
ment of PKCa is sufficient to bind TGFbRI, suggesting a kinase-
substrate relationship (Figure S4A).
TGFbRI Is a Direct Substrate of PKCa
By using in vitro kinase assays, we showed that PKCa is able
to induce TGFbRI phosphorylation. Here, inclusion of TGFbRII,
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Figure 2. PKCa-Deficient Mice Are Resistant to EAE in a Passive Adoptive-Transfer Model
For adoptive EAE, draining lymph-node cells and splenocytes fromMOG35-55-immunizedWT, Prkca
/, or PBS-treatedWT (control) mice were restimulated with
MOG35-55 in the presence of Th17-cell-polarizing cytokines for 3 days. Data in (A)–(E) were derived from fivemice per group. (See also Figure S2). Error bars in (B),
(C), (E), and (F) represent ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
(A and B) Representative FACS dot plots of IL-17A+ and IFN-g+ cells (CD4+ gated) are displayed in (A), and the quantification is shown in (B).
(C) IFN-g (left) and IL-17A (right) levels were measured.
(D and E) Representative FACS dot plots of ROR-gt+ cells (CD4+ gated) are displayed in (D), and the quantification is shown in (E).
(F) Disease time course of adoptive EAE inWT recipients, reconstitutedwith Th17-cell-polarizedWT (n = 4),Prkca/ (n = 4), or control CD4+-enriched (n = 2) cells.
Of note, control mice injected with cells fromPBS-injectedWTmice and stimulated in vitro for 3 days withMOG33-35 under Th17-cell-polarizing conditions did not
show any disease signs.
(G) Naive CD4+ OT-II T cells were stimulated with OVA323-339-pulsed DCs under Th17-cell-polarizing conditions. Cells were stained for Va2TCR and intracellular
IL-17A and analyzed by flow cytometry. Representative FACS plots of two independent experiments of three mice per group are shown.
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PKCa Is a Positive Regulator of TGFbR Functiontogether with PKCa, led to a synergistic phosphorylation of
TGFbRI. In addition, TGFbRI phosphorylation was reduced by
a PKCa-specific inhibitor (Figure 4A). Predicting PKC-mediated
phosphorylation sites led to the identification of T200 on TGFbRI
as a bona fide candidate PKC-mediated phosphorylation site.
The experimental investigation indicated that the T200WT
TGFbRI peptide, but not the T200Vmutant motif, was phosphor-
ylated by PKCa (Figure 4B). TGFbRII additively acts with PKCa to
induce phosphorylation of T200WT, but not the T200V mutant,
TGFbRI motif. Next, we evaluated the presence of this phospho-
site on endogenous TGFbRI by using a (p)T200-site-specificantiserum that was raised for this investigation (Figure S4B).
Both immunoblot (Figure 4C) and intracellular flow cytometry
showed that phosphorylation of T200 on TGFbRI was induced
by TGFb in WT, but not Prkca/, CD4+ T cells (Figures 4D and
4E). Although we cannot exclude the existence of additional
PKCa-mediated phosphorylation sites, the above results from
the use of the (p)T200 TGFbRI antibody suggest that T200
on TGFbRI is a PKCa-mediated phosphorylation site in intact
T cells. Notably, the T200 site is in close proximity to the estab-
lished binding site of the immunophilin FKBP1A on TGFbRI.
During steady state, FKBP1A bound to TGFbRI counteractsImmunity 38, 41–52, January 24, 2013 ª2013 Elsevier Inc. 45
Table 2. Transfer of MOG35-55-Specific Th17 Cells into WT 129sv
Recipients
Genotype
Incidence
(ScoreR 0.5)
Onset Day
(Mean ± SEM)
Maximum Score
(Mean ± SEM)
Control 0% (0/2) NA NA
WT 100% (4/4) 5.00 ± 0.41 2.25 ± 0.25
Prkca/ 100% (4/4) 14.00 ± 3.24* 0.50 ± 0.00***
The results are shown as the mean ± SEM and indicate the total number
of individual mice. The following abbreviations are used: WT, wild-type;
and NA, not applicable. *p < 0.05; ***p < 0.001.
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PKCa Is a Positive Regulator of TGFbR Functionligand-independent unspecific phosphorylation of TGFbRI by
TGFbRII. However, TGFb-ligand-induced receptor activation
causes the release of FKBP1A from TGFbRI (Chen et al., 1997;
Shi and Massague´, 2003). Cotransfection with constitutively
active PKCa significantly diminished binding of FKBP1A to
the WT TGFbRI (Figure 4F; lanes 1 and 6), which was rescued
when the phosphorylation-defective T200V TGFbRI mutant
was cotransfected (Figure 4F; lanes 6 and 8). Moreover, the
phosphomimic T200D TGFbRI mutant completely failed to bind
FKBP1A (Figure 4F; lanes 2 and 7). As a control, T204 alterations
in TGFbRI did not show this effect. These data suggest that
phosphorylation of T200 on TGFbRI by PKCa might lead to an
induced displacement of FKBP1A from the TGFbRI. Collectively,
these data suggest a physical and functional TGFbRI-PKCa
interaction that might regulate efficient TGFbRI kinase-activation
responses.
PKCa Does Not Play a Role in Noncanonical
TGFb-Mediated Signaling Pathways
TGFb is known to also signal via noncanonical pathways
(Moustakas and Heldin, 2005). However, to this point, we have
been unable to detect a substantial TGFb-induced activation
of the noncanonical TGFb-signaling pathways p38 mitogen-
activated protein (MAP) kinase, stress-activated protein kinase
(SAPK)/Jun amino-terminal kinase (JNK), extracellular-signal-
regulated kinases 1 and 2 (ERK1/2), or protein kinase B (PKB
or AKT) in primary T cells (Figures S5A–S5H), consistent with
observations of other groups (Cejas et al., 2010; Chang et al.,
2011). Nevertheless, we observed no difference in the activation
levels between WT and Prkca/ cells. Furthermore, SMAD-
independent TGFb-mediated downregulation of eomesodermin
(Ichiyama et al., 2011) remains unaffected in the absence of
PKCa (Figure S5I).
PKCa Is a Critical Signaling Intermediate of the SMAD-
Dependent TGFbRI-Signaling Pathway
The investigation of the canonical, SMAD-dependent TGFbRI-
signaling pathway led to the striking observation that the
phosphorylation of both SMAD2 and SMAD3 is impaired in
Prkca/ CD4+ T cells (Figures 5A and 5C). In addition, the treat-
ment of WT CD4+ T cells with a PKCa-specific inhibitor led to
a complete phenocopy of Prkca/ cells, indicating that the
PKCa catalytic activity is required to activate the canonical
TGFbRI-SMAD2-3 pathway (Figures 5B and 5C). Similarly, trans-
fection of Jurkat T cells with a kinase-dead PKCa mutant con-
struct repressed the induction of a SMAD-dependent promoter
luciferase reporter (Figure 5D). At the same time, both WT and46 Immunity 38, 41–52, January 24, 2013 ª2013 Elsevier Inc.Prkca/ naive CD4+ T cells expressed similar SMAD2,
SMAD3, and SMAD4 levels (Figure 5E and data not shown).
By using band-shift assays, we identified a strong defect in
SMAD2-3 DNA-binding activity in both genetically deleted and
pharmacologically PKCa-inhibited cells (Figures 5F–5H). Taken
together, our data suggest that PKCa acts as a positive regulator
of SMAD2-3-mediated TGFb signaling in T cells and that its dele-
tion results in reduced sensitivity to the biologic effects of TGFb.
Interestingly, the SBE has been located upstream of the Il2
promoter, which is important for SMAD-mediated transcriptional
suppression of IL-2 (Tzachanis et al., 2001). Moreover, it was
demonstrated that TGFb suppresses IL-2 production of T cells
(Brabletz et al., 1993) in a SMAD3-dependent manner (McKarns
et al., 2004). In order to elucidate the connection between
the impaired TGFb-mediated SMAD-signaling cascade and the
severely reduced IL-17A Th17 cell effector responses in the
absence of PKCa, we investigated IL-2 amounts. Interestingly,
we observed substantially elevated IL-2 amounts in Th17 cell
cultures (Figure 5I), as well as in MOG35-55 EAE-recall samples
(Figure 1N) in the absence of PKCa. A recent study (Yang
et al., 2011) supports a model in which the balance of IL-6-
induced STAT3- and IL-2-triggered STAT5-DNA-binding capa-
bilities directly dictates the outcome of IL-17A production.
Indeed, by using band-shift assays, we observed a severely
impaired STAT binding to the minimal Il17a promoter region in
Prkca/ CD4+ T cells, stimulated under Th17-cell-polarizing
conditions (TGFb + IL-6) (Figure 5J). Furthermore, ChIP analysis
revealed a notably reduced STAT3 DNA binding to the same
Il17a promoter region in WT Th17 cells treated with a PKCa-spe-
cific inhibitor (data not shown), as well as in Prkca/ Th17 cells
(Figure 5K).
DISCUSSION
TGFbR signaling plays an essential role in the generation of
iTreg and Th17 cells, yet little is known about whether TGFbR-
triggered pathways might make use of linage-specific activators
of TGFbR signaling. Here, we report that CD4+ T cells lacking
PKCa function exhibit a specific Th17 cell defect in vitro and
during neuroinflammatory disease in vivo. Our data of the hypo-
susceptibility of Prkca/ mice to EAE induction and the sub-
stantial reduction of IL-17A+ and IFN-g+ CNS cell infiltrates
demonstrate that PKCa is critical for the control of IL-17A tran-
scription. Supporting our findings of IL-17A+IFN-g+ cells in
Prkca/ mice during EAE, there exists sophisticated evidence
that Th17 cells have considerable plasticity toward a Th1 cell
phenotype in EAE by producing both IL-17A and IFN-g (Ivanov
et al., 2006; Zhou et al., 2009). With the use of mouse systems
tracking reporter Th cell fate, it has been shown that IL-17A-
producing cells are reprogrammed to produce both IL-17A and
IFN-g or even IFN-g alone during EAE (Hirota et al., 2011; Kur-
schus et al., 2010). Thus, we speculate that this robust IFN-g-
production defect observed in Prkca/ Th17 cells during EAE
disease progression is secondary to the IL-17A defect.
Mice deficient in IL-17A exhibit delayed onset, reduced scores
of maximum severity, ameliorated histological changes, and
early recovery of EAE (Ishigame et al., 2009; Komiyama et al.,
2006; Nakae et al., 2003; Yang et al., 2008a). Moreover, it has
been shown that in vivo neutralization of IL-17A significantly
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Figure 3. Physical Interaction between PKCa and TGFbRI
(A) IL-17A levels were assessed of cells differentiated with the indicated Th17-cell-favoring cytokines.
(B) The mRNA transcript levels of TGFbRI and TGFbRII of naive CD4+ T cells were determined with qRT-PCR. The results are presented relative to WT levels.
(C) Flow-cytometry analysis of TGFbRII surface expression of naive CD4+ T cells. A representative FACS histogram (CD4+ gated) and quantification of the mean
fluorescence intensity (MFI) per cell are shown.
(D) The expression level of TGFbRI in CD4+ T cells, stimulated with TGFb as indicated, was detected by IB. One representative blot from at least four independent
experiments that yielded similar results is shown.
(E and F) Levels of IL-17A (E) and IL-17F (F) were assessed of cells differentiated with the indicated TGFb concentrations after 3 days of Th17 cell
differentiation.
(legend continued on next page)
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Figure 4. PKCa Phosphorylates T200 on TGFbRI
(A) Kinase assays of the glutathione S-transferase (GST) fusion protein of the cytoplasmic subdomain of TGFbRI (amino acids 148–503) were incubated with
recombinant PKCa and TGFbRII as indicated. Phosphorylation was detected by autoradiography. The GST-antibody immunoblot (lower panel) confirmed equal
loading.
(B) The phosphorylation rates of T200WT and T200V mutant motifs were measured by the incorporation of 32Pi from g
32P-ATP incubated with PKCa and/or
TGFbRII kinases. The following abbreviation is used: cpm, counts per minute.
(C) Naive CD4+ T cells were stimulated with TGFb as indicated. TGFb-inducible phosphorylation of T200 on TGFbRI was observed in WT cells, but not Prkca/
cells, as shown by a representative IB.
(D and E) The intracellular induction by (p)T200 on TGFbRI with the (p)T200-specific antibody and the quantification of the percent induction of MFI are shown. In
(E), the error bars represent ± SEM. *p < 0.05.
(F) Cotransfection of Jurkat T cells with constitutively active A25E PKCa significantly diminished binding of FKBP1A to the WT TGFbRI, but not the neutral-
exchange T200V mutant of TGFbRI. Representative data were derived from at least two independent experiments.
(See also Figure S4).
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PKCa Is a Positive Regulator of TGFbR Functionreduces the severity of EAE (Hofstetter et al., 2005; Komiyama
et al., 2006; Uyttenhove and Van Snick, 2006). However, there
exist some contradictory data on the relative importance of IL-
17A during EAE (El-Behi et al., 2011; Haak et al., 2009), but the
consensus view is that IL-17A clearly plays a pathogenic role
in EAE and MS. Nevertheless, we cannot exclude additional
PKCa-mediated effects (next to IL-17A) for the apparent EAE
benefit in Prkca/ mice.
We observed that the decreased IL-17A levels do not correlate
with a decreased ROR-gt expression in Prkca/ Th17 cells.
Consistently, changes in IL-17A expression can be independent
of ROR-gt expression, as observed in other studies (Acosta-Ro-
driguez et al., 2007; Kaminski et al., 2011; Tzartos et al., 2008).(G and H) Representative confocal immunofluorescence (G) and quantification (H
human CD4+ PBMCs.
(I and J) Representative single confocal section overlays of cells stimulated with
(G and I) Colors are as follows: green, PKCa; red, TGFbRI; yellow, merged; and
resented as white spots.
(K) Endogenous binding between PKCa and TGFbRI in CD3+ T cells. TGFbRI anti
and analyzed by IB with a PKCa antibody.
(L) Naive WT CD4+ T cells were stimulated with TGFb and analyzed for expressio
Data in (A)–(C), (E), and (F) were derived from two independent experiments of thre
independent experiments. Error bars in (A)–(C), (E), (F), (H), (J), and (L) represent
48 Immunity 38, 41–52, January 24, 2013 ª2013 Elsevier Inc.Interestingly, we observed a reduced population of FOXP3+
cells in Prkca/ CNS tissues during acute EAE. This counterin-
tuitive finding might merely reflect a reduced recruitment of
FOXP3+ iTreg cells as a result of the curtailed inflammatory stim-
ulus in Prkca/ mice. Interestingly, several reports (Chen et al.,
2011; Veldhoen et al., 2006b) underpinned a potential pathologic
function of iTreg cells by showing that FOXP3+ iTreg cells
empowered rather than inhibited Th17 cell differentiation during
chronic inflammatory conditions in vivo. Thus, we could specu-
late that the reduced presence of FOXP3+ cells in CNS tissues
of Prkca/ mice during EAE even represents a beneficial,
though until this point undefined, mechanism. Our results sup-
port the notion that PKCa is not required to effectively induce) of the colocalization of PKCa and TGFbRI in untreated (ctr) or TGFb-treated
TGFb (2 min) (I). Quantitative colocalization analysis is shown in (J).
purple, gp130. The scale bars represent 5 mm. All pixels colocalized are rep-
body or normal IgG antibody (control IP) was used for the immunoprecipitation
n of PKCa.
e to four mice per group. Data in (D), (L), and (K) were derived from at least three
± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. (See also Figure S3).
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Figure 5. The Activation of SMAD2 and SMAD3 by TGFbRI Critically Depends on PKCa
(A andB) IB shows that TGFb stimulation leads to SMAD2 and SMAD3phosphorylation inWT cells yet is hindered in bothPrkca/ cells (A) and cells preincubated
with PKC LMWI (low-molecular-weight inhibitor) (B). CD4+ T cells were treated with TGFb as indicated, and nuclear extracts (NEs) were generated.
(C) Graphs represent the fold induction of normalized nuclear levels of selected TGFb concentrations (0 and 5 ng/ml) of (p)SMAD2 (left) and (p)SMAD3 (right).
(D) Transfection of the catalytically inactive kinase-dead K368R PKCa mutant (but not the WT) expression vector in Jurkat T cells repressed the expression of
a SMAD2-3-dependent promoter luciferase reporter.
(E) IB analysis confirmed equal total-protein expression levels of SMAD2 and SMAD3 between WT and Prkca/ CD4+ T cell lysates.
(F and G) Reduced SMAD2-3 DNA binding to the SMAD-binding element (SBE) in both Prkca/ cells and PKC-LMWI-preincubated cells, as determined by
electromobility shift assays (EMSA). CD4+ T cells were treated with TGFb as indicated, and NEs were generated.
(H) The graph represents the fold induction of normalized SMAD2-3-DNA-binding efficiency.
(I) IL-2 levels were analyzed in Th17-cell-differentiated WT and Prkca/ cells. Data are from four independent experiments.
(J) EMSA analysis of the binding capability of an Il17a minimal promoter oligonucleotide, containing a consensus STAT binding site and incubated with WT or
Prkca/ NEs of cells that were stimulated as indicated (2 hr). Resting cells were used as unspecific controls.
(K) Chromatin immunoprecipitation (ChIP) analysis (for 16 hr) of the binding capability of STAT3 to the minimal Il17a promoter in Th17-cell (TGFb + IL-6)-primed,
WT, or Prkca/ CD4+ T cells. Data are from two independent experiments.
Representative blots are from two (J) or at least three (A, B, and E–G) independent experiments that yielded similar results. In (C) and (H), the results are presented
relative to unstimulated WT levels and are normalized to the expression levels of DNA polymerase-d, and data were pooled from at least three independent
experiments. Error bars in (C), (D), (H), (I), and (K) represent the mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. (See also Figure S5).
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PKCa Is a Positive Regulator of TGFbR FunctioniTreg cell functions and reveal an unexpectedly selective role for
PKCa in TGFbR signaling in Th17 cells.
Mechanistically, we have shown that PKCa deficiency renders
T cells less sensitive to TGFb-induced SMAD2-3 activation. Of
note, the cellular role of SMAD2-3 signaling in Th17 and iTreg
cells is not without controversy in the literature given that two
studies showed that SMAD2 is especially important for the
optimal induction of Th17 cells (Malhotra et al., 2010; Takimoto
et al., 2010), whereas another report (Martinez et al., 2009)
indicated that SMAD3-activation defects increase Th17 celleffector functions. However, in agreement with our investiga-
tions, a recent study demonstrated that the enhanced genera-
tion of Th17 cells is associated with increased TGFb-induced
SMAD2-3 activation (Cejas et al., 2010).
Th17 cell commitment represents a dynamic balance between
the DNA-binding of STAT3 and STAT5 to sites along the single
Il17a–Il17f locus. Furthermore, STAT5 DNA binding is associated
with displacement of STAT3 within the Il17a promoter region
(Yang et al., 2011). Here, we provide strong experimental data
that the absence of PKCa abrogates STAT3 DNA accessibilityImmunity 38, 41–52, January 24, 2013 ª2013 Elsevier Inc. 49
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PKCa Is a Positive Regulator of TGFbR Functionto the minimal Il17a promoter region in Th17 cells. Thus, it is
tempting to speculate that in Prkca/ Th17 cells, IL-2 hyper-
production, which is secondary to the defects in SMAD2-3
activation, might lead to increased efficiency of STAT5 DNA
binding, thereby displace STAT3 from this locus, and ultimately
result in the observed inhibition of IL-17A transcription. Impor-
tantly, another study (Cejas et al., 2010) has also suggested
that a main function of TGFb in early Th17 cell differentiation
might be the inhibition of IL-2-mediated suppression of Th17
cell generation.
Given the selective IL-17A expression defect, which does not
affect IL-17F expression, in Prkca/ Th17 cells, it is important to
mention that the Il17a promoter is established to be primarily
responsive to STAT3, whereas the Il17f promoter is largely
responsive to ROR-gt (Thomas et al., 2012). Accordingly, it has
been demonstrated that at high IL-6 concentrations, IL-17F, in
strict contrast to IL-17A, is insensitive to IL-2-mediated inhibition
(Yang et al., 2011). Given the present data, we can hypothesize
that this selective PKCa-dependent Th17 cell defect during
TGFbR signaling is due to constrained STAT3 binding to the
Il17a promoter.
In this study, direct regulation of the canonical TGFbRI-
SMAD pathway by PKCa appeared to be mediated at the
level of T200 phosphorylation on TGFbRI. Intriguingly, the
T200V alteration has been identified to severely inhibit TGFbRI
kinase activity and consequently TGFb-dependent activation
responses (Wieser et al., 1995). However, the protein kinase
that is responsible for the physiological phosphorylation of this
candidate phosphosite has not been defined to date. Given the
obtained results, one possible function of PKCa might be to
modulate FKBP1A binding on TGFbRI, and the T200 phosphos-
witch, located within the critical interaction surfaces of these two
binding partners, might alter local electrostatic potential to per-
turb the intermolecular interaction with FKBP1A, required for
effective negative TGFbRI kinase regulation.
Collectively, this study extends the paradigm underlying
TGFbRI activation in the efficient generation of Th17 cell immune
responses. Consistent with human genetic data that link poly-
morphisms of PRKCA (encoding PKCa) to the Th17-cell-based
pathogenesis of MS (Barton et al., 2004; Saarela et al., 2006),
our findings reveal an essential immunomodulatory function of
PKCa. Intriguingly, because PKC inhibitors are in clinical trials
(Baier and Wagner, 2009), our findings could provide a rational
mechanistic basis for the treatment of certain Th17-cell-medi-
ated immune pathologies.
EXPERIMENTAL PROCEDURES
Mice
The generation of the Prkca/ mice was described previously (Pfeifhofer
et al., 2006). All animal studies complied with the current laws and were
approved by the authors’ respective institutional review boards.
Th Cell Differentiation
Naive CD4+ T cells were isolated with a CD4+CD62Lhi T cell isolation kit II
(Miltenyi Biotec), and the Th-cell-subset differentiation (3 days) was performed
in RPMI or IMDM (for Th17 cell differentiation) as previously described (Her-
mann-Kleiter et al., 2008). In brief, the Th-cell-neutral (Th0) conditions con-
tained neither exogenous cytokines nor blocking antibodies. The other condi-
tions were as follows: Th1 = mIL-12 (10 ng/ml) and aIL-4 (5 mg/ml); Th2 = IL-4
(10 ng/ml), aIL-12 (5 mg/ml), and IFN-g (5 mg/ml); Th17 = TGFb (5 ng/ml), IL-650 Immunity 38, 41–52, January 24, 2013 ª2013 Elsevier Inc.(40 ng/ml), IL-1a (20 ng/ml), aIL-4 (2 mg/ml), and aIFN-g (2 mg/ml); and
iTreg = TGFb (10 ng/ml), IL-2 (10 ng/ml), aIFN-g (5 mg/ml), aIL-12 (5 mg/ml),
and aIL-4 (5 mg/ml). Naive CD4+ OT-II T cells were stimulated with 2.5 3 105
LPS (100 ng/ml)-activated splenic CD11c+ DCs (DC:T cell = 1:4) and pulsed
with 1 mM OVA-peptide323-339 (Genscript) in the presence of Th17-cell-polar-
izing cytokines for 3 days.
Analysis of Cytokine Production
The cytokine amount in culture supernatants was determined with BioPlex
multianalyte technology (Biorad) on day 3 of Th cell differentiation according
to the manufacturer’s instructions. For IL-4 and TGFb analysis in Th2 and
Th17 cell cultures, respectively, cells were washed after 3 days of differentia-
tion and restimulated with 2 mg/ml plate-bound CD3 antibody for 24 hr
in serum-free X-vivo 20 medium. The supernatant was used for cytokine
analysis.
EAE Assay and Preparation of CNS Mononuclear Cells
The EAE assay and the preparation of CNS mononuclear cells have been
previously described (Hermann-Kleiter et al., 2008).
Passive Adoptive EAE
The general procedure was adapted, with minor modifications, to reports
in Axtell et al., 2010, Ja¨ger et al., 2009, and Komiyama et al., 2006. Spleno-
cyte suspensions were generated from MOG35-55-immunized (day 10) WT,
Prkca/, or WT PBS-treated control mice. Splenocytes were restimulated
with 25 mg/ml MOG35-55 under Th17-cell-polarizing conditions for 3 days.
CD4+ T cells were purifiedwith aMACS (Miltenyi Biotec) kit, and 1.53 107 cells
were transferred into healthyWT recipient mice (intraperitoneally [i.p.]). In addi-
tion, pertussis toxin (Sigma; 200 ng/mouse) was administered i.p. on the day of
the adoptive transfer and 48 hr later. Signs of EAE were assigned scores on
a scale of 0–4 (Hermann-Kleiter et al., 2008).
Coimmunoprecipitation Analysis
The coimmunoprecipitation analysis was described previously (Gruber et al.,
2009). In brief, a total of 5 3 107 murine CD3+ T cells were lysed, precleared,
and incubated with 2 mg of PKCa antibody (Millipore) overnight. Unspecific
IgG Ab was used as a negative control. Thereafter, samples were incubated
with protein G sepharose (Amersham-Pharmacia), washed in lysis buffer,
and resolved by SDS-PAGE.
Gel Shift Assay
NEs were harvested from 1 3 107 to 2 3 107 CD4+ T cells according to stan-
dard protocols. In brief, CD4+ T cells were isolated with the CD4+ T cell Isola-
tion Kit (Miltenyi Biotec) and rested for 1.5 hr in X-vivo 20 (37C, 5% CO2); this
was followed by various stimulation conditions (as indicated). Cells were re-
suspended in 10 mM HEPES (pH 7.9), 10 mM KCl, 0.1 mM EDTA, 0.1 mM
EGTA, 1mM dithiothreitol (DTT), and protease inhibitors. Cells were incubated
on ice for 15 min. NP-40 was then added to a final concentration of 0.6%, the
cells were vigorously mixed, and the mixture was centrifuged for 5 min at
2,300 rpm 3 g. The nuclear pellets were resuspended in 20 mM HEPES
(pH 7.9), 0.4 MNaCl, 1mMEDTA, 1mMEGTA, 1mMDTT, and protease inhib-
itors, and the tubes ware rocked for 30 min at 4C. After centrifugation at
13,400 rpm 3 g, the supernatants were collected and stored at 80C for
further analysis. Nuclear protein extracts (2–7 mg) were incubated in binding
buffer with the end-labeled, double-stranded oligonucleotide SBE probe
(SBE consensus oligonucleotide [sc-2603]: 50-AGTATGTCTAGACTGA-30) as
described previously (Kaminski et al., 2011). The following WT and mutated
oligonucleotides were used, and the core binding motifs for STAT are under-
lined for the minimal Il17a promoter: 50-TCTGTTCAGCTCCCAAGAAGTCA
TGCTTCTTTGCATAGTGAACTTCTGCC-30 (Stat) and 50-TCTGTACAGCTCC
CAAGCAGTCATGCTACTTTGCATAGTGTACTGCTGCC-30 (Stat mu). The
band shifts were resolved on a 5% polyacrylamide gel.
RNA Transcript Analysis by qRT-PCR
The gene-expression analysis has been previously described (Kaminski et al.,
2011). For qRT-PCR analysis, cells were restimulated with plate-bound CD3
antibody (2 mg/ml) for 4 hr. Data were normalized to GAPDH mRNA and are
presented relative to Th0 levels.
Immunity
PKCa Is a Positive Regulator of TGFbR FunctionStatistical Analysis
The p values were calculated with an unpaired Student’s t test. Significant
differences are indicated as *p < 0.05, **p < 0.01, and ***p < 0.001.
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